{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:25:43Z","timestamp":1783733143615,"version":"3.55.0"},"reference-count":55,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Roche Diagnostics International Ltd"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With recent advances in disease-modifying therapies for Alzheimer's disease (AD), demand for confirmatory biomarker testing such as via cerebrospinal fluid (CSF) analysis or amyloid positron emission tomography (PET) will increase considerably for diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the current capacity and estimating the anticipated future need of AD confirmatory testing in the United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based decision tree model was employed to simulate the AD diagnostic pathway for patients presenting with symptoms of mild cognitive impairment or mild dementia in primary and secondary care in the US. All patients were assumed to be enrolled in Medicare. The study was conducted from the US payer's perspective over a 5-year period. Four scenarios assessed the impact of different utilization patterns: (1) reference scenario (current use in AD diagnostic pathway:\u2009&lt;\u20091% amyloid-PET; 3.5% CSF analysis); (2) increased CSF analysis utilization scenario (50% utilization); (3) amyloid-PET only; and (4) CSF analysis only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Scenario 1 fails to meet the growing demand for AD confirmatory testing (assumed annual care-seeking rate of 50%), with approximately 0.3% of all amyloid-\u03b2-positive patients receiving a timely and accurate diagnosis with amyloid-PET, and 1.7% with CSF analysis. Scenarios 2 and 4 resulted in the highest proportion of accurate and timely diagnoses for amyloid-\u03b2-positive patients (24.8% and 44.6%, respectively) versus 15.1% of patients in scenario 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>It is imperative to address capacity issues for AD confirmatory testing to facilitate timely diagnosis and initiation of amyloid-targeting therapies. Increasing CSF analysis utilization has the capacity to meet this growing demand.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251406909","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:02:58Z","timestamp":1768896178000},"page":"1458-1470","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The capacity for Alzheimer's disease confirmatory testing in the United States: The current situation and simulations for future increase"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-5693","authenticated-orcid":false,"given":"Sophie","family":"Roth","sequence":"first","affiliation":[{"name":"Global Access &amp; Policy, Roche Diagnostics International Ltd, Rotkreuz, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Yan","sequence":"additional","affiliation":[{"name":"Information Solutions Division, Roche Diagnostics, Santa Clara, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Magdalena","family":"Patru","sequence":"additional","affiliation":[{"name":"Neurology, Medical and Scientific Affairs, Roche Diagnostics, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Mattke","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gustavsson","sequence":"additional","affiliation":[{"name":"Real World Evidence and Analytics, Quantify Research AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ortsater","sequence":"additional","affiliation":[{"name":"Real World Evidence and Analytics, Quantify Research AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01314-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0069-5"},{"key":"e_1_3_3_5_2","article-title":"Editorial: targets for disease-modifying therapies in Alzheimer's disease, including amyloid \u03b2 and tau protein","volume":"27","author":"Parums DV","year":"2021","unstructured":"Parums DV. Editorial: targets for disease-modifying therapies in Alzheimer's disease, including amyloid \u03b2 and tau protein. Med Sci Monit 2021; 27: e934077.","journal-title":"Med Sci Monit"},{"key":"e_1_3_3_6_2","unstructured":"Eisai Inc. US prescribing information: LEQEMBI\u00ae (lecanemab-irmb) injection for intravenous use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf (2023 accessed March 2025)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150692"},{"key":"e_1_3_3_8_2","unstructured":"Eli Lilly. US prescribing information: KISUNLA (donanemab-azbt) injection for intravenous use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf (2024 accessed March 2025)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.001"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14528"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12470"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Liu JL Hlavka JP Hillestad R et al. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment https:\/\/www.rand.org\/pubs\/research_reports\/RR2272.html (2017 accessed March 2025).","DOI":"10.7249\/RR2272"},{"key":"e_1_3_3_14_2","article-title":"Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment","volume":"13","author":"Lam J","year":"2021","unstructured":"Lam J, Jun H, Cho SK, et al. Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment. Alzheimers Dement (Amst) 2021; 13: e12159.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_15_2","article-title":"Real-world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee-for-service beneficiaries","volume":"17","author":"Yan JT","year":"2025","unstructured":"Yan JT, Dillon A, Meng T, et al. Real-world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee-for-service beneficiaries. Alzheimers Dement (Amst) 2025; 17: e70156.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03340-9"},{"key":"e_1_3_3_17_2","unstructured":"IMV. 2022 PET imaging market summary report https:\/\/imvinfo.com\/product\/2022-pet-imaging-market-summary-report\/ (2022 accessed March 2025)."},{"key":"e_1_3_3_18_2","unstructured":"CMS.gov. Beta Amyloid positron emission tomography in dementia and neurodegenerative disease: CAG-00431R https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&ncaid=308 (2025 accessed March 2025)."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101544"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_21_2","unstructured":"United States Census Bureau. 2023 National population projections tables: main series https:\/\/www.census.gov\/data\/tables\/2023\/demo\/popproj\/2023-summary-tables.html (2023 accessed March 2025)."},{"key":"e_1_3_3_22_2","unstructured":"CMS.gov. July 2024 Medicare monthly enrollment https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/medicare-monthly-enrollment\/\/data (2024 accessed March 2025)."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00335-x"},{"key":"e_1_3_3_24_2","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke S","year":"2020","unstructured":"Mattke S, Cho SK, Bittner T, et al. Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. Alzheimers Dement (Amst) 2020; 12: e12081.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2000"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.4668"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5216"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.10.001"},{"key":"e_1_3_3_29_2","article-title":"Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment","volume":"3","author":"Lombardi G","year":"2020","unstructured":"Lombardi G, Crescioli G, Cavedo E, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. Cochrane Database Syst Rev 2020; 3: CD009628.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"e_1_3_3_32_2","unstructured":"CMS.gov. Physician fee schedule guide https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search (2023 accessed March 2025)."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.23"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2023.270"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.24"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4235\/agmr.20.0082"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12778"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01272-z"},{"key":"e_1_3_3_40_2","unstructured":"OECD. OECD health statistics https:\/\/www.oecd.org\/en\/data\/datasets\/oecd-health-statistics.html (2021 accessed March 2025)."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170078"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S228939"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0516"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00595-5"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12919"},{"key":"e_1_3_3_46_2","article-title":"Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, elecsys and lumipulse, with Amyloid PET status","volume":"13","author":"Willemse EAJ","year":"2021","unstructured":"Willemse EAJ, Tijms BM, van Berckel BNM, et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, elecsys and lumipulse, with Amyloid PET status. Alzheimers Dement 2021; 13: e12182.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13762"},{"key":"e_1_3_3_48_2","article-title":"Clinical application of CSF biomarkers for Alzheimer's disease: from rationale to ratios","volume":"14","author":"Bouwman FH","year":"2022","unstructured":"Bouwman FH, Frisoni GB, Johnson SC, et al. Clinical application of CSF biomarkers for Alzheimer's disease: from rationale to ratios. Alzheimers Dement (Amst) 2022; 14: e12314.","journal-title":"Alzheimers Dement (Amst)"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00393-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00274-0"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13244"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-022-00269-x"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0079-7"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592302"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333468"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251406909","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251406909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:53Z","timestamp":1777370993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251406909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/13872877251406909"],"URL":"https:\/\/doi.org\/10.1177\/13872877251406909","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}